Viking Therapeutics Inc. stocks have been trading up by 7.54 percent after promising obesity drug trial data fueled investor optimism.
Key Takeaways
- Truist assumed coverage with a Buy rating and lifted its VKTX price target to $83, pointing to strong early obesity data and both injectable and oral drug formats supporting long-term use.
- Lake Street started coverage with a Buy and an $89 target, modeling roughly $3B in risk-adjusted global VK2735 sales by 2040 as VKTX leans into the obesity megatrend.
- Street-wide consensus on VKTX is firmly Buy, with an average price target of $94.62, suggesting analysts see meaningful upside from current trading levels.
- A new Chief Medical Officer, Hubert C. Chen, M.D., joins Viking Therapeutics to steer late-stage obesity and NASH programs VK2735 and VK2809 toward potential commercialization.
- Management will meet with B. Riley in Denver on 2026/06/22, giving traders another catalyst for fresh commentary on the VKTX pipeline and timelines.
Live Update At 17:03:36 EDT: On Tuesday, June 23, 2026 Viking Therapeutics Inc. stock [NASDAQ: VKTX] is trending up by 7.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
VKTX has been acting like a classic momentum biotech with real news behind it. Over the past few weeks, Viking Therapeutics shares have climbed from a close near $28 on 2026/06/12 to about $34.81 on 2026/06/23. That’s a solid multi-day trend higher, not a random spike.
Look at the intraday tape from the most recent session. VKTX opened around the low $30s and pushed steadily to hit $35 into the close, with buyers stepping in on dips and holding each pullback. That kind of grind — higher highs, higher lows on the 5‑minute chart — tells traders that real demand is there, not just algos chasing headlines.
More Breaking News
- PURR Stock Slips As Liquidity Stays Strong And Speculative Capital Shifts
- Ouster Stock Surges as Rev8 Deals Signal Autonomy Push
- INFQ Stock Grinds Higher As Traders Focus On Cash And Volatility
- TE Stock Grinds Higher As Traders Watch Key Levels
On the fundamentals side, Viking Therapeutics is still a clinical-stage story. The latest quarterly report shows a net loss of about $158M, driven mainly by roughly $150M in research and development spend. VKTX is burning cash, with free cash flow around -$114M, but it also ended the quarter with about $603M in cash and short-term investments and zero debt. A current ratio near 5.7 means VKTX has a sizable runway to fund trials, which is key for traders tracking dilution risk and binary data events.
Why Traders Are Watching VKTX Momentum
VKTX is sitting in the middle of one of the hottest themes in the market: obesity drugs. Viking Therapeutics has captured Street attention as data from its GLP‑1/GIP agonist VK2735 looks competitive in a crowded space. Truist stepping in with a Buy rating and an $83 price target is one marker of that shift. The firm highlighted strong early obesity efficacy, no plateau at 13 weeks, and both injectable and oral versions — all features traders know matter for real-world adherence and, by extension, revenue potential.
Lake Street piled on with its own Buy rating and an $89 target, going further by modeling roughly $3B in risk-adjusted global VK2735 sales by 2040. That’s important. It tells traders that Wall Street is starting to view VKTX less like a tiny speculative biotech and more like a future commercial obesity platform. Add in the broader analyst consensus Buy and an average target near $94.62, and you get a setup where pullbacks can quickly attract dip-buying.
VKTX is also tightening up execution. The company appointed Hubert C. Chen, M.D., as Chief Medical Officer to run clinical development and regulatory strategy as VK2735 and NASH candidate VK2809 move toward late-stage trials. For traders, that’s a classic “de-risking the path” move. You want serious regulatory experience in the chair before big phase 3 reads and potential filings.
Finally, management’s upcoming 2026/06/22 meeting with B. Riley in Denver is another potential headline catalyst. Any color on trial design, timelines, or commercialization plans can move VKTX fast. With the stock trending up and the Street leaning bullish, traders will be watching that event tape closely.
Conclusion
VKTX is a textbook example of how a biotech story can transform once the Street decides the science has real commercial legs. Viking Therapeutics has lined up multiple Buy ratings, rising price targets into the $80s and $90s, and a long-term VK2735 sales model that puts the company squarely in the obesity heavyweight conversation. At the same time, VKTX still carries the financial profile of a high-risk, high-reward clinical name: heavy R&D loss, negative earnings, but a strong cash pile and no debt.
For active traders, that mix is exactly where momentum and volatility are born. The recent run from the high $20s to the mid‑$30s has been supported by steady buying and clear news catalysts, not just message-board hype. VKTX is building a narrative — differentiated obesity data, dual formulations, a credible CMO, and a focused NASH asset — that traders can track and trade around future data drops and conference appearances.
The key is to respect both sides of the coin. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” That mindset complements his other core lesson to his students: “Trade like a sniper, not a machine gun — wait for the best setups, and always cut losses quickly.” VKTX will offer big swings as news hits. For disciplined traders who study the charts, know the catalysts, and manage risk, Viking Therapeutics may stay on the watchlist for a long time. This analysis is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply